sequencing bispecific antibodies in myeloma - bcma or gprc5d? | rahul banerjee, md | ims 2024
Published 1 month ago • 33 plays • Length 7:34Download video MP4
Download video MP3
Similar videos
-
58:19
sequencing bcma myeloma therapies
-
19:00
symposium | beyond bcma: novel strategies using bispecific antibodies
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
3:43
regn5458 bispecific antibody | naresh bumma, md | ims 2022
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
1:24
bispecifics & cars: bcma, gprc5d & fcrh5 sequencing
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
3:28
the importance of bcma-targeting adcs and bispecific antibodies in r/r multiple myeloma
-
2:19
bispecific antibodies in myeloma
-
4:26
what are bispecific antibodies?
-
14:00
what are bispecific antibodies? #myeloma
-
22:48
symposium | bcma-directed bispecific antibodies
-
1:47
linker-mm1: linvoseltamab, a bispecific antibody, in r/r multiple myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
0:55
what are bispecific antibodies?
-
6:09
bispecific antibodies | high impact topic (hit)
-
30:24
faqs on bmca-targeted bispecific antibodies in multiple myeloma